-
Has The Mainstream Media Finally Turned Against Bill Gates?
-
Cancel Culture and the Bankruptcy of Liberalism
-
Implanted wireless device triggers mice to form instant bond
-
How America Became the Money Laundering Capital of the World
-
The Inevitable Yo-Yo Ride of Pandemic Fortresses
-
Rules-based international order: NATO, Goldman Sachs and the Council on Foreign Relations
-
Report Reveals Major Corporations Are Funding Lawmakers Behind Anti-Democracy Bills
-
Teen Hospitalized With Blood Clots in Brain After First Dose of Pfizer Vaccine
-
The Trump administration spied on journalists. The Biden administration defended it
-
Big Pharma Creates COVID Vaccination Wristbands To Help Speed Up Checkpoint Passage
-
The State That Executed a Black Child Wants to Bring Back the Firing Squad
-
California declares drought emergency across vast swath of state
-
Agroforestry: An ancient practice with a promising future?
-
Despite Massive Push, Survey Finds Just 29% Of Parents Want COVID Vaccine For Kids
-
American Pravda: “The Truth” and “The Whole Truth” About the Origins of Covid-19
Ginger treatment for blocking inflammation
Researchers identify antioxidant properties of a ginger-derived compound that may help fight inflammatory diseases
Nara Institute of Science & Technology (Japan), May 7, 2021
Many natural compounds have various anti-inflammatory and other beneficial properties that humans have been utilizing for medicinal purposes for hundreds of years. However, the specific molecular mechanisms behind these health-promoting effects are not always clear. One such compound is 1′-acetoxychavicol acetate, or ACA, which comes from the tropical ginger Alpinia plant. Now, researchers from Nara Institute of Science and Technology (NAIST) have identified how ACA can help in the treatment of inflammatory diseases.
In a report published in International Immunology, they found that ACA attenuates mitochondrial damage through decreasing mitochondrial reactive oxygen species (ROS), blocking activation of a crucial protein complex known as the nucleotide-binding oligomerization domain-like receptor family pyrin domain-containing protein 3 (NLRP3) inflammasome. Many inflammatory diseases, like inflammatory bowel disease, display improper and chronic activation of this complex.
Previous work has suggested that the NLRP3 inflammasome plays a significant role in promoting inflammation by secreting a molecule called IL-1ß. This acts as a messenger that recruits various immune cells to the site of injury or infection. Additional studies described how production of ROS can help trigger activation of the NLRP3 inflammasome. Because other groups showed that ACA can reduce ROS production in certain immune cells, the NAIST researchers became curious how this compound would impact the NLRP3 inflammasome and its functions.
“Many disease pathogeneses involve dysregulation of the inflammasome,” says Daisuke Ori, co-lead author on the study. “Blood cells from people suffering from rheumatoid arthritis or other autoimmune disorders frequently have increased levels of inflammasome-derived IL-1ß. Therefore, targeting the NLRP3 inflammasome with a compound like ACA may be a promising therapeutic strategy.”
The researchers grew immune cells in culture that were obtained from mouse bone marrow, and also used a mouse model of colitis. ACA was added to the growing cells and the live mice were given the compound in their food. The researchers then examined the effects on ROS production, secretion of IL-1ß, and other markers of inflammation.
“Cells treated with ACA had significantly reduced IL-1ß production, as well as lower levels of ROS,” explains Taro Kawai, senior author. “ACA could also inhibit NLRP3 inflammasome activation in the colitis mouse model.” These in vivo results are promising, as they suggest ACA has the potential to treat or prevent the development of inflammatory diseases. “Interestingly, we did not observe high levels of immune cell death when using ACA, which means that it may be relatively safe,” continues Ori.
This work provides novel evidence for a specific molecular mechanism governing the previously observed anti-inflammatory properties of ACA. Furthermore, it highlights the potential of ACA for therapeutic use in diseases mediated by IL-1ß molecules, or associated with cytokine storm occurrence, as seen in patients suffering from severe COVID-19.
Feeling younger buffers older adults from stress, protects against health decline
Younger ‘subjective age’ can have functional health benefits, study finds
German Center of Gerontology, May 6, 2021
People who feel younger have a greater sense of well-being, better cognitive functioning, less inflammation, lower risk of hospitalization and even live longer than their older-feeling peers. A study published by the American Psychological Association suggests one potential reason for the link between subjective age and health: Feeling younger could help buffer middle-aged and older adults against the damaging effects of stress.
In the study, published in Psychology and Aging, researchers from the German Centre of Gerontology analyzed three years of data from 5,039 participants in the German Ageing Survey, a longitudinal survey of residents of Germany age 40 and older. The survey included questions about the amount of perceived stress in peoples’ lives and their functional health – how much they were limited in daily activities such as walking, dressing and bathing. Participants also indicated their subjective age by answering the question, “How old do you feel?”
The researchers found, on average, participants who reported more stress in their lives experienced a steeper decline in functional health over three years, and that link between stress and functional health decline was stronger for chronologically older participants.
However, subjective age seemed to provide a protective buffer. Among people who felt younger than their chronological age, the link between stress and declines in functional health was weaker. That protective effect was strongest among the oldest participants.
“Generally, we know that functional health declines with advancing age, but we also know that these age-related functional health trajectories are remarkably varied. As a result, some individuals enter old age and very old age with quite good and intact health resources, whereas others experience a pronounced decline in functional health, which might even result in need for long-term care,” said study lead author Markus Wettstein, PhD, who is now at University of Heidelberg. “Our findings support the role of stress as a risk factor for functional health decline, particularly among older individuals, as well as the health-supporting and stress-buffering role of a younger subjective age.”
The results suggest that interventions that aim to help people feel younger could reduce the harm caused by stress and improve health among older adults, according to the researchers – though further study is needed to help determine what kind of interventions would work best. For example, Wettstein said, messaging campaigns to counteract ageism and negative age stereotypes and to promote positive views on aging could help people feel younger. In addition, more general stress-reduction interventions and stress management training could prevent functional health loss among older adults, according to Wettstein.
Finally, more research is needed to figure out the ideal gap between subjective and chronological age, according to Wettstein, as previous research has suggested that it’s helpful to feel younger up to a point but that benefits decrease as the gap between subjective and chronological age increases. “Feeling younger to some extent might be adaptive for functional health outcomes, whereas ‘feeling too young’ might be less adaptive or even maladaptive,” he said.
Creatine may be protective against reduced cognitive performance in older population
University of Novi Sad (Serbia), May 5, 2021
According to news reporting originating in Novi Sad, Serbia, research stated, “Recent clinical trials suggested a potential benefit of dietary creatine on cognitive function for aging individuals. However, the association between creatine consumption from food and cognitive function in the older adults remained undetermined at the populational level.”
The news reporters obtained a quote from the research from the University of Novi Sad, “The present study quantified the amount of creatine consumed through a regular diet among U.S. adults aged 60 years and over, and evaluated the link between dietary creatine and cognitive function using data from the 2001-2002 National Health and Nutrition Examination Survey (NHANES). NHANES 2001-2002 round included a total of 1340 older adults (51.8% women; age 71.4 ± 7.8 years) who provided valid dietary information and cognitive testing measures. Dietary intake information was obtained from the NHANES Dietary Data component through a 24-h in-person dietary recall interview. Cognitive function was assessed using the WAIS III Digit Symbol Substitution Test (DSS) conducted during the household interview. A bivariate model revealed a significant positive correlation between DSS scores and creatine intake across the whole sample (tb = 0.043; P = 0.02). The partial models demonstrated a significant correlation between creatine consumption and DSS score when adjusted for sociodemographic variables (r = 0.062; P = 0.039), and nutritional variables (r = 0.055; P = 0.049). The participants who consumed more than 0.95 g of creatine per day (3rd and 4th quartiles of creatine intake) were found to have higher scores on the cognitive functioning test as compared to their peers with lower creatine intake (1st and 2nd quartiles) (P < 0.05). Our findings suggest that creatine from food might be protective against reduced cognitive performance in the older population.”
According to the news reporters, the research concluded: “Further research is highly warranted to investigate the role of dietary creatine amount in cognitive function in the older adults.”
This research has been peer-reviewed.
5:2 diet helps reduce skin symptoms in Psoriasis patients
Ghent University (Belgium), 6 May, 2021
New research investigating for the first time the effects of modified intermittent fasting (MIF) on the skin of people with psoriasis has yielded promising results. Preliminary study findings presented today at the EADV Spring Symposium, show a significant reduction in scaling and thickness in patients with mild psoriasis after following a MIF 5:2 diet (eating normally for 5 days and restricting calorie intake on 2 non-consecutive days).
Psoriasis is a chronic, systemic immune-mediated inflammatory disease that causes raised plaques and scales on the skin’s surface. The disease affects between 2-3% of the worlds’ adult population, and <1% of children. Until now, the effect of dietary interventions on psoriasis severity has rarely been investigated, and although it is known that there is a link between obesity and psoriasis severity1, the mechanism of action of this link is still unclear. This study sought to provide mechanistic evidence to inform whether there is a link between gut health and psoriatic lesions, as well as uncover any benefits of MIF in psoriasis management.
“We had observed positive results in mice with gut inflammation and psoriasis, with inflammation in the gut driving cutaneous symptoms,” shares Dr Lynda Grine, Postdoctoral Researcher, Department of Dermatology, Ghent University, Belgium “Through scientific curiosity and my own experience with fasting as a Muslim, I wanted to find out whether dietary intervention would have the same effects on human patients with psoriasis.”
MIF is a form of intermittent fasting which requires participants to restrict calorie intake for a certain amount of time. It is often viewed as a more manageable form of fasting, allowing participants to adjust the rules to accommodate with their personal lives. Popular MIF diets include the 16:8 (fast for 16 hours and eat for 8) and 5:2 diet, with the latter being used as the dietary intervention for this study.
A total of 24 subjects were enrolled in the study, with one group of 12 participants instructed to modify their diet with MIF for 12 weeks, and the other 12 participants continuing on their regular diet. Replicating the 5:2 diet, the fasting group were asked to consume a total of 500 kcal twice per week on 2 non-consecutive days, but were free to consume their usual daily calorie intake for the remaining 5 days of the week. During the trial, 2 patients were excluded: 1 due to start of antibiotic use and 1 due to loss to follow-up.
Objectively, PASI (a tool used to measure the severity and extent of psoriasis) and Body Surface Area (BSA) did not differ significantly between fasting and regular diet, although PASI reduced in the fasting group (p<0.05). Waist circumference and weight were comparable at 6 weeks but reduced significantly in the fasting group at week 12 compared to the control group (p<0.05 and <0.001, respectively). Fasting subjects reported significant improvement more frequently at weeks 6 and 12 (p<0.0001), mentioning less scaling and thickening, with 30% of patients also reporting a decrease in itching. The study will be completed at the end of June.
“The effect of dietary interventions on skin health is a stimulating field of research in dermatology. The results of this study add to the growing body of evidence being undertaken to understand the relationship between the gut and skin, with some promising results for patients and the disease management of psoriasis.” Says Prof. Marie-Aleth Richard, EADV Board Member and Professor at the University Hospital of La Timone, Marseille.
Zinc acetate lozenges may increase the recovery rate from the common cold by 3 fold
University of Helsinki (Finland), May 11, 2021
According to a meta-analysis of three randomized controlled trials zinc acetate lozenges may increase the rate of recovery from the common cold three fold. On the fifth day, 70% of the zinc lozenge patients had recovered compared with 27% of the placebo patients.
The effect of zinc acetate lozenges was not modified by age, sex, race, allergy, smoking, or baseline common cold severity. Therefore the 3-fold increase in the recovery rate from common cold may be widely applicable. While some zinc lozenges have an unpleasant taste, the zinc acetate lozenges used in these three randomized trials did not suffer from such a problem.
The dose of zinc in the three studies was between 80 to 92 mg/day. Such doses are substantially higher than the recommended daily zinc intake in the USA, which is 11 mg/day for men and 8 mg/day for women. However, in certain other controlled studies, unrelated to the common cold, zinc has been administered in doses of 100 to 150 mg/day to patients for months with few adverse effects. Furthermore, 150 mg/day zinc is a standard treatment for Wilson’s disease that requires treatment for the rest of a patient’s life. Therefore, it seems highly unlikely that 80-92 mg/day of zinc for one to two weeks, starting very soon after the onset of the first cold symptoms, might lead to long-term adverse effects. None of the three analyzed zinc lozenge studies observed serious adverse effects of zinc.
Even though there is strong evidence that properly formulated zinc acetate lozenges can increase the rate of recovery from the common cold by 3 fold, many zinc lozenges on the market appear to have either too low doses of zinc or they contain substances that bind zinc ions, such as citric acid. Therefore, the findings of this meta-analysis should not be directly extrapolated to the wide variety of zinc lozenges on the current market.
Although the lead author, Dr. Harri Hemilä from the University of Helsinki, Finland, suggests that the optimal formulation of zinc lozenges and the best frequency of their administration should be further investigated, he also instructs common cold patients to test individually whether zinc lozenges are helpful for them: “given the strong evidence of efficacy and the low risk of adverse effects, common cold patients may already be encouraged to try zinc acetate lozenges not exceeding 100 mg of elemental zinc per day for treating their colds.”
Sugar-sweetened drinks linked to increased risk of colorectal cancer in women under 50
Sugary beverage consumption in adolescence, young adulthood associated with increased risk
Washington University School of Medicine, May 6, 2021
Colorectal cancer diagnoses have increased among people under age 50 in recent years and researchers are seeking reasons why. A new study led by Washington University School of Medicine in St. Louis has found a link between drinking sugar-sweetened beverages and an increased risk of developing colorectal cancer in women under age 50. The findings suggest that heavy consumption of sugary drinks during adolescence (ages 13 to 18) and adulthood can increase the disease risk.
The study, published online May 6 in the journal Gut, provides more support for public health efforts that encourage people to reduce the amount of sugar they consume.
“Colorectal cancer in younger adults remains relatively rare, but the fact that the rates have been increasing over the past three decades — and we don’t understand why — is a major public health concern and a priority in cancer prevention,” said senior author Yin Cao, ScD, an associate professor of surgery and of medicine in the Division of Public Health Sciences at Washington University. “Due to the increase in colorectal cancer at younger ages, the average age of colorectal cancer diagnosis has gone down from 72 years to 66 years. These cancers are more advanced at diagnosis and have different characteristics compared with cancers from older populations.
“Our lab is funded by the National Cancer Institute (NCI) and the National Comprehensive Cancer Network to identify risk factors, the molecular landscapes, and precision screening strategies for these cancers so that they can be detected earlier and even prevented,” said Cao, who also has a master’s of public health. “In past work, we have shown that poor diet quality was associated with increased risk of early-onset colorectal cancer precursors, but we have not previously examined specific nutrients or foods.”
Compared with women who drank less than one 8-ounce serving per week of sugar-sweetened beverages, those who drank two or more servings per day had just over twice the risk of developing early-onset colorectal cancer, meaning it was diagnosed before age 50. The researchers calculated a 16% increase in risk for each 8-ounce serving per day. And from ages 13 to 18, an important time for growth and development, each daily serving was linked to a 32% increased risk of eventually developing colorectal cancer before age 50.
Sugar-sweetened drink consumption has been linked to metabolic health problems, such as type 2 diabetes and obesity, including in children. But less is known about whether such high-sugar beverages could have a role in the increasing incidence of colorectal cancer in younger people. Like early-onset colorectal cancer rates, consumption of such drinks has increased over the past 20 years, with the highest consumption level found among adolescents and young adults ages 20 to 34.
The researchers analyzed data from the Nurses’ Health Study II, a large population study that tracked the health of nearly 116,500 female nurses from 1991 to 2015. Every four years, participants answered surveys that included questions about diet, including the types and estimated amounts of beverages they drank. Of the total participants, over 41,000 also were asked to recall their beverage habits during their adolescence.
The researchers identified 109 diagnoses of early-onset colorectal cancer among the nearly 116,500 participants.
“Despite the small number of cases, there is still a strong signal to suggest that sugar intake, especially in early life, is playing a role down the road in increasing adulthood colorectal cancer risk before age 50,” said Cao, also a research member of Siteman Cancer Center. “This study, combined with our past work linking obesity and metabolic conditions to a higher risk of early-onset colorectal cancer, suggests that metabolic problems, such as insulin resistance, may play an important role in the development of this cancer in younger adults.”
With the increasing rates in mind, the American Cancer Society has recently lowered the recommended age for a first screening colonoscopy to 45, down from the previously recommended age 50 for people at average risk. Those with additional risk factors, such as a family history of the disease, should start even earlier, according to the guidelines.
Since the study only included female nurses, most of whom were white, more work is needed to examine this link in people of more diverse races, ethnicities and genders.
While sugar-sweetened beverages were linked to an increased risk of early-onset colorectal cancer, some other drinks — including milk and coffee — were associated with a decreased risk. This observational study can’t demonstrate that drinking sugary beverages causes this type of cancer or that drinking milk or coffee is protective, but the researchers said that replacing sweetened beverages with unsweetened drinks, such as milk and coffee, is a better choice for long-term health.
“Given this data, we recommend that people avoid sugar-sweetened beverages and instead choose drinks like milk and coffee without sweeteners,” Cao said.
Researchers explore the therapeutic effects of Yarrow
Tehran University of Medical Sciences, May 7, 2021
Iranian researchers investigated the therapeutic effects of Achillea wilhelmsii (AW) extract on indomethacin-induced gastric lesion in rats, from both proteomic and metabolomic perspectives. Their findings listed below were published in the BMC Complementary and Alternative Medicine.
- Gastric ulcer is one of the most prevalent diseases worldwide.
- In Iranian folk medicine, AW is used to treat gastric ulcer.
- Previous studies have found that AW also has anti-ulcerogenic properties.
- For their experiment, the researchers divided rats into four groups and induced gastric ulcer using a single dose of indomethacin (45 mg/kg).
- They then administered 800 mg/kg of the AW extract orally to one group for 10 days.
- The researchers collected serum and tissue samples for further investigation and conducted spectrometric analyses for the metabolomic study.
- For the proteomic analysis, they conducted 2D gel electrophoresis followed by liquid chromatography coupled with mass spectrometry.
- Relevant genes were confirmed using real time PCR.
- Both macroscopic and microscopic investigations confirmed the effectiveness of the AW extract.
- The researchers reported that a panel of metabolites showed altered expression levels during gastric lesion development.
- The levels of some of these metabolites returned to nearly their normal values after the administration of the AW extract.
- The researchers also observed changes in the levels of some proteins, including albumin, fatty acid-binding protein 5 (Fabp5), heat shock protein beta-1 (Hspb1), transgelin (Tagln), galectin-7 (Lgals7), cystatin-A (Csta) and myosin regulatory light polypeptide-9 (Myl9).
- AW treatment reversed the changes in the levels of these proteins caused by the gastric lesion formation.
Based on these findings, the researchers concluded that A. wilhelmsii is a potential therapy for indomethacin-induced gastric lesions
